Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Purchased by SeaCrest Wealth Management LLC

SeaCrest Wealth Management LLC raised its stake in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 15.0% during the 1st quarter, Holdings Channel reports. The institutional investor owned 17,600 shares of the biotechnology company’s stock after buying an additional 2,300 shares during the period. SeaCrest Wealth Management LLC’s holdings in Anavex Life Sciences were worth $151,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Vermillion Wealth Management Inc. acquired a new position in shares of Anavex Life Sciences in the 4th quarter worth approximately $34,000. Tower Research Capital LLC TRC boosted its holdings in shares of Anavex Life Sciences by 102.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company’s stock worth $36,000 after buying an additional 1,708 shares during the period. Prudential Financial Inc. acquired a new position in shares of Anavex Life Sciences in the fourth quarter worth about $109,000. D.A. Davidson & CO. acquired a new position in shares of Anavex Life Sciences in the fourth quarter worth about $122,000. Finally, AlphaQuest LLC acquired a new stake in shares of Anavex Life Sciences during the fourth quarter worth approximately $146,000. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Trading Down 4.1%

Shares of AVXL stock opened at $7.93 on Tuesday. Anavex Life Sciences Corp. has a 1 year low of $3.51 and a 1 year high of $14.44. The firm’s fifty day simple moving average is $8.41 and its 200 day simple moving average is $9.07. The firm has a market capitalization of $677.00 million, a P/E ratio of -14.42 and a beta of 0.68.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. During the same quarter in the prior year, the business posted ($0.13) earnings per share. Equities research analysts anticipate that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. D. Boral Capital restated a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a report on Monday, April 7th. HC Wainwright restated a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a report on Monday, April 7th.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.